Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Screening methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments

CV. Hulzebos, L. Vitek, CD. Coda Zabetta, A. Dvořák, P. Schenk, EAE. van der Hagen, C. Cobbaert, C. Tiribelli

. 2021 ; 90 (2) : 272-276. [pub] 20210503

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012334
E-zdroje Online Plný text

NLK Free Medical Journals od 1967 do Před 1 rokem
ProQuest Central od 2016-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2016-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2016-01-01 do Před 1 rokem

Severe neonatal hyperbilirubinemia (SNH) is a serious condition that occurs worldwide. Timely recognition with bilirubin determination is key in the management of SNH. Visual assessment of jaundice is unreliable. Fortunately, transcutaneous bilirubin measurement for screening newborn infants is routinely available in many hospitals and outpatient settings. Despite a few limitations, the use of transcutaneous devices facilitates early recognition and appropriate management of neonatal jaundice. Unfortunately, however, advanced and often costly screening modalities are not accessible to everyone, while there is an urgent need for inexpensive yet accurate instruments to assess total serum bilirubin (TSB). In the near future, novel icterometers, and in particular optical bilirubin estimates obtained with a smartphone camera and processed with a smartphone application (app), seem promising methods for screening for SNH. If proven reliable, these methods may empower outpatient health workers as well as parents at home to detect jaundice using a simple portable device. Successful implementation of ubiquitous bilirubin screening may contribute substantially to the reduction of the worldwide burden of SNH. The benefits of non-invasive bilirubin screening notwithstanding, any bilirubin determination obtained through non-invasive screening must be confirmed by a diagnostic method before treatment. IMPACT: Key message: Screening methods for neonatal hyperbilirubinemia facilitate early recognition and timely treatment of severe neonatal hyperbilirubinemia (SNH). Any bilirubin screening result obtained must be confirmed by a diagnostic method. What does this article add to the existing literature? Data on optical bilirubin estimation are summarized. Niche research strategies for prevention of SNH are presented. Impact: Transcutaneous screening for neonatal hyperbilirubinemia contributes to the prevention of SNH. A smartphone application with optical bilirubin estimation seems a promising low-cost screening method, especially in low-resource settings or at home.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012334
003      
CZ-PrNML
005      
20220506130148.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41390-021-01543-1 $2 doi
035    __
$a (PubMed)33941863
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hulzebos, Christian V $u Beatrix Children's Hospital, University Medical Center Groningen, Groningen, The Netherlands. c.v.hulzebos@umcg.nl
245    10
$a Screening methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments / $c CV. Hulzebos, L. Vitek, CD. Coda Zabetta, A. Dvořák, P. Schenk, EAE. van der Hagen, C. Cobbaert, C. Tiribelli
520    9_
$a Severe neonatal hyperbilirubinemia (SNH) is a serious condition that occurs worldwide. Timely recognition with bilirubin determination is key in the management of SNH. Visual assessment of jaundice is unreliable. Fortunately, transcutaneous bilirubin measurement for screening newborn infants is routinely available in many hospitals and outpatient settings. Despite a few limitations, the use of transcutaneous devices facilitates early recognition and appropriate management of neonatal jaundice. Unfortunately, however, advanced and often costly screening modalities are not accessible to everyone, while there is an urgent need for inexpensive yet accurate instruments to assess total serum bilirubin (TSB). In the near future, novel icterometers, and in particular optical bilirubin estimates obtained with a smartphone camera and processed with a smartphone application (app), seem promising methods for screening for SNH. If proven reliable, these methods may empower outpatient health workers as well as parents at home to detect jaundice using a simple portable device. Successful implementation of ubiquitous bilirubin screening may contribute substantially to the reduction of the worldwide burden of SNH. The benefits of non-invasive bilirubin screening notwithstanding, any bilirubin determination obtained through non-invasive screening must be confirmed by a diagnostic method before treatment. IMPACT: Key message: Screening methods for neonatal hyperbilirubinemia facilitate early recognition and timely treatment of severe neonatal hyperbilirubinemia (SNH). Any bilirubin screening result obtained must be confirmed by a diagnostic method. What does this article add to the existing literature? Data on optical bilirubin estimation are summarized. Niche research strategies for prevention of SNH are presented. Impact: Transcutaneous screening for neonatal hyperbilirubinemia contributes to the prevention of SNH. A smartphone application with optical bilirubin estimation seems a promising low-cost screening method, especially in low-resource settings or at home.
650    _2
$a bilirubin $x krev $7 D001663
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a časná diagnóza $7 D042241
650    _2
$a lidé $7 D006801
650    _2
$a novorozenecká hyperbilirubinemie $x krev $x diagnóza $x terapie $7 D051556
650    _2
$a novorozenec $7 D007231
650    _2
$a novorozenecká žloutenka $x krev $x diagnóza $x terapie $7 D007567
650    _2
$a mobilní aplikace $7 D063731
650    12
$a novorozenecký screening $x přístrojové vybavení $7 D015997
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a prognóza $7 D011379
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a chytrý telefon $7 D000068997
650    _2
$a upregulace $7 D015854
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Vitek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics and 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Coda Zabetta, Carlos D $u Bilimetrix s.r.l., Trieste, Italy
700    1_
$a Dvořák, Aleš $u Institute of Medical Biochemistry and Laboratory Diagnostics and 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Schenk, Paul $u Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands
700    1_
$a van der Hagen, Eline A E $u Dutch Foundation for Quality Assessment in Medical Laboratories (SKML), Nijmegen, The Netherlands $u MCA Laboratory, Queen Beatrix Hospital, Winterswijk, The Netherlands
700    1_
$a Cobbaert, Christa $u Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands
700    1_
$a Tiribelli, Claudio $u Italian Liver Foundation, Trieste, Italy
773    0_
$w MED00003741 $t Pediatric research $x 1530-0447 $g Roč. 90, č. 2 (2021), s. 272-276
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33941863 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130140 $b ABA008
999    __
$a ok $b bmc $g 1789780 $s 1163535
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 90 $c 2 $d 272-276 $e 20210503 $i 1530-0447 $m Pediatric research $n Pediatr Res $x MED00003741
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...